Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of several solid tumours, including metastatic colorectal cancer, small cell lung cancer, ovarian cancer and gastric cancer, in adult oncology patients, and is indicated for use in combination chemotherapy regimens.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant facilities and pharmacies worldwide, ensuring quality‑assured product availability across global markets.

Irinotecan is used in oncology to treat solid tumours that are responsive to topoisomerase I inhibition.

- Metastatic colorectal cancer: improves survival when combined with other chemotherapeutic agents. - Small cell lung cancer: used as part of multi‑drug regimens for disease control. - Ovarian cancer: contributes to tumour reduction in advanced stages. - Gastric cancer: incorporated into combination therapy to enhance response rates.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities. - Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe colitis or intestinal perforation: life‑threatening gastrointestinal complications. - Anaphylactic reactions: rare hypersensitivity requiring immediate intervention. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Severe electrolyte disturbances: especially hypokalemia and hyponatremia. - Cardiac arrhythmias: uncommon but possible in vulnerable patients.

Before initiating Irinotecan therapy, clinicians should evaluate several safety parameters.

- Monitor blood counts: perform regular CBCs to detect neutropenia early. - Assess liver function: obtain baseline and periodic LFTs as hepatic impairment alters drug metabolism. - Maintain hydration: ensure adequate fluid intake to mitigate severe diarrhea. - Avoid strong CYP3A4 inhibitors: concurrent use may increase Irinotecan exposure and toxicity. - Pregnancy and lactation: prescribe only when potential benefits justify potential risks to the fetus or infant. - Store at ambient temperature: keep in original container, protect from light and moisture.

Irinotecan can interact with other medicines, influencing its safety and effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise Irinotecan plasma levels and toxicity. - Concurrent myelosuppressive agents: increase risk of severe bone‑marrow suppression. - Live vaccines: heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic efficacy. - Anticholinergic drugs: can exacerbate constipation associated with Irinotecan. - Warfarin: may alter INR and affect anticoagulation control.